Company Overview and News

 
ETF Managers Trust DEFINITIVE MATERIALS FOR XBRL

2017-02-13 sec.gov
Filed Pursuant to Rule 497(c) 1933 Act Registration File No. 333-182274 1940 Act File No. 811-22310 EXPLANATORY NOTE On behalf of ETF Managers Trust and pursuant to Rule 497(c) under the Securities Act of 1933, as amended, attached for filing are XBRL exhibits containing interactive data format risk/return summary information that mirrors the fees and expenses table risk/return summary information contained in the definitive Prospectus dated January 31, 2017, for  BlueStar TA-BIGITech Israel Tec

 
ETF Managers Trust XBRL TAXONOMY EXTENSION SCHEMA

2017-02-13 sec.gov
000001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 020000 - Document - Risk/Return Summary {Unlabeled} - BlueStar TA-BIGITech ™ Israel Technology ETF link:presentationLink link:definitionLink link:calculationLink 020001 - Schedule - Annual Fund Operating Expenses link:presentationLink link:definitionLink link:calculationLink 020002 - Schedule - Expense Example {Transposed} link:presentationLink link:definitionLink link:calculationLi

 
ETF Managers Trust POST EFFECTIVE AMENDMENT - RULE 485B FOR XBRL

2017-02-13 sec.gov
As filed with the U.S. Securities and Exchange Commission on February 13, 2017 File No.  333-182274 File No.:  811-22310 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-1A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ☒ Pre‑Effective Amendment No.             ☐ Post‑Effective Amendment No. 54 ☒ and/or  REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 ☒ Amendment No.

 
ETF Managers Trust DEFINITIVE MATERIALS

2017-02-01 sec.gov
      BlueStar TA-BIGITech™ Israel Technology ETF (ITEQ) Listed on NASDAQ   PROSPECTUS January 31, 2017 Fund shares are not individually redeemable by the Fund but trade on the NASDAQ in individual share lots. THE SEC HAS NOT APPROVED OR DISAPPROVED THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. Table of Contents - Prospectus for BlueStar TA-BIGITechTMIsrael Technology ETF About This Prospectus   This prospec

 
ETF Managers Trust DEFINITIVE MATERIALS

2017-02-01 sec.gov
    PureFunds® ISE Big Data™ ETF (BIGD) PureFunds® ISE Mobile Payments™ ETF (IPAY) PureFunds® ISE Cyber Security™ ETF (HACK) PureFunds® ISE Junior Silver™ (Small Cap Miners/Explorers) ETF (SILJ) PureFunds Drone Economy Strategy ETF (IFLY) PureFunds Video Game Tech ETF (GAMR) each listed on NYSE Arca, Inc. PureFunds Solactive FinTech ETF (FINQ) PureFunds ETFx HealthTech ETF (IMED) each listed on The NASDAQ Stock Market LLC Each Fund is a series of ETF Managers Trust PROSPECTUS January 31, 2017 TH

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-02-01 sec.gov
PureFundsTM ISE Junior Silver (Small Cap Miners/Explorers) ETF Trading Symbol:  SILJ Listed on NYSE Arca   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM ISE Junior Silver (Small Cap Miners/Explorers) ETF’s (the “Fund” or the “Junior Silver ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
Tierra XP Latin America Real Estate ETF Trading Symbol: LARE Listed on NYSE Arca Summary Prospectus January 31, 2017   www.tierrafunds.com Before you invest, you may want to review the Tierra XP Latin America Real Estate ETF’s (the “Fund”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are incorporated by reference into this

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
PureFundsTM Drone Economy Strategy ETF Trading Symbol: IFLY Listed on NYSE Arca   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM Drone Economy Strategy ETF’s (the “Fund” or the “Drone Economy ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are incorporate

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
PureFundsTM ETFx HealthTech ETF Trading Symbol: IMED Listed on The NASDAQ Stock Market LLC   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM ETFx HealthTech ETF’s (the “Fund” or the “ETFx Health Tech ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are inco

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
PureFundsTM ISE Mobile Payments ETF Trading Symbol: IPAY Listed on NYSE Arca   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM ISE Mobile Payments ETF’s (the “Fund” or the “Mobile Payments ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are incorporated by

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
PureFundsTM ISE Big Data ETF Trading Symbol: BIGD Listed on NYSE Arca   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM ISE Big Data ETF’s (the “Fund” or the “Big Data ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are incorporated by reference into this

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
PureFundsTM Solactive FinTech ETF Trading Symbol: FINQ Listed on The NASDAQ Stock Market LLC   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM Solactive FinTech ETF’s (the “Fund” or the “Solactive FinTech ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
    BlueStar TA-BIGITech™ Israel Technology ETF Trading Symbol: ITEQ Listed on NASDAQ   Summary Prospectus January 31, 2017   www.iteqetf.com Before you invest, you may want to review the BlueStar TA-BIGITech™ Israel Technology ETF’s (the “Fund”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are incorporated by reference in

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
PureFundsTM Video Game Tech ETF Trading Symbol: GAMR Listed on NYSE Arca   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM Video Game Tech ETF’s (the “Fund” or the “Video Game Tech ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are incorporated by referen

 
ETF Managers Trust SUMMARY PROSPECTUS

2017-01-31 sec.gov
PureFundsTM ISE Cyber Security ETF Trading Symbol:  HACK Listed on NYSE Arca   Summary Prospectus January 31, 2017   www.PureETFs.com Before you invest, you may want to review the PureFundsTM ISE Cyber Security ETF’s (the “Fund” or the “Cyber Security ETF”) statutory prospectus and statement of additional information, which contain more information about the Fund and its risks.  The current statutory prospectus and statement of additional information dated January 31, 2017, are incorporated by r

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...